research Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer: Impact of CDK4/6 Inhibitors on the Current Treatment Paradigm
CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
Search
forLearn
0 / 0 results — no results
Research
5 / 215 results 
research Safety and Patient-Reported Outcomes in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated With CDK4/6 Inhibitors in China: A Cross-Sectional Study
Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
research CDK4/6 Inhibition Mitigates Stem Cell Damage in a Novel Model for Taxane-Induced Alopecia
CDK4/6 inhibitors can protect hair cells from chemotherapy damage.
research Fatigue, Alopecia, and Stomatitis Among Patients With Breast Cancer Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors: A Systematic Review and Meta-Analysis
Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.
research Retrospective Cohort Study of CDK4/6-Inhibitor-Induced Alopecia in Patients With Breast Cancer
CDK4/6 inhibitors may cause hair loss in breast cancer patients.
Community Join
0 / 0 results — no results